A phase 1 study of XL019 a selective JAK2 inhibitor, in patients with primary myelofibrosis and, post-polycythemia vera/essential thrombocythemia myelofibrosis

被引：12
|
作者：
Verstovsek, Srdan [1 ]
Pardanani, Animesh D. [2 ]
Shah, Neil P. [3 ]
Sokol, Lubomir [4 ]
Wadleigh, Martha [5 ]
Gilliland, D. Gary
List, Alan F. [4 ]
Tefferi, Ayalew [2 ]
Kantarjian, Hagop M. [1 ]
Bui, Lynne A. [6 ]
Clary, Douglas O. [6 ]
机构：
[1] MD Anderson Canc Ctr, San Francisco, CA USA
[2] Mayo Clin, San Francisco, CA USA
[3] Univ Calif San Francisco, San Francisco, CA USA
[4] H Lee Moffitt Canc Ctr & Res Inst, San Francisco, CA USA
[5] Dana Farber Canc Inst, San Francisco, CA USA
[6] Exelixis Inc, San Francisco, CA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.553.553
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
553
引用
收藏
页码：170A / 170A
页数：1
相关论文
共 50 条
  • [1] A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
    Shah, Neil P.
    Olszynski, Patrycja
    Sokol, Lubomir
    Verstovsek, Srdan
    Hoffman, Ronald
    List, Alan F.
    Cortes, Jorge
    Kantadian, Hagop M.
    Gilliland, D. Gary
    Clary, Douglas O.
    Bui, Lynne A.
    Wadleigh, Martha
    BLOOD, 2008, 112 (11) : 44 - 44
  • [2] A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera
    Paquette, Ronald
    Sokol, Lubomir
    Shah, Neil P.
    Silver, Richard T.
    List, Alan F.
    Clary, Douglas O.
    Bui, Lynne A.
    Talpaz, Moshe
    BLOOD, 2008, 112 (11) : 971 - 971
  • [3] Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Santos, Fabio P. S.
    Kantarjian, Hagop M.
    Jain, Nitin
    Manshouri, Taghi
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Kennedy, Debra
    Estrov, Zeev
    Cortes, Jorge
    Verstovsek, Srdan
    BLOOD, 2010, 115 (06) : 1131 - 1136
  • [4] Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen K.
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Rivera, Candido E.
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2016, 128 (22)
  • [5] A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2015, 126 (23)
  • [6] Phase II Study of Sunitinib in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
    Apostolidou, Effrosyni
    Kantarjian, Hagop
    Thomas, Deborah
    Burger, Ian
    Borthakur, Gautam
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (04): : 281 - 284
  • [7] PHASE II STUDY OF CEP-701, AN ORALLY AVAILABLE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
    Santos, F. P. S.
    Kantarjian, H.
    Jain, N.
    Thomas, D.
    Garcia-Manero, G.
    Cortes, J.
    Verstovsek, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 439 - 439
  • [8] Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis
    Verstovsek, Srdan
    Tefferi, Ayalew
    Korriblau, Steven
    Thomas, Deborah
    Cortes, Jorge
    Ravandi-Kashani, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2007, 110 (11) : 1037A - 1037A
  • [9] Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis
    Komrokji, Rami S.
    Wadleigh, Martha
    Seymour, John F.
    Roberts, Andrew W.
    To, Luen Bik
    Zhu, Huan J.
    Mesa, Ruben A.
    BLOOD, 2011, 118 (21) : 130 - 131
  • [10] GERMLINE HOMOZYGOSITY FOR JAK2 46/1 HAPLOTYPE IS A RISK FACTOR OF DEVELOPING PRIMARY OR POST-POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
    Andrikovics, H.
    Nahajevszky, S.
    Koszarska, M.
    Meggyesi, N.
    Bors, A.
    Halm, G.
    Lueff, S.
    Lovas, N.
    Matrai, Z.
    Csomor, J.
    Rasonyi, R.
    Egyed, M.
    Varkonyi, J.
    Mikala, G.
    Sipos, A.
    Kozma, A.
    Adam, E.
    Tordai, A.
    Masszi, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 408 - 408
12345